Disease relevance of cefotaxime

• More recently, reported studies showed enhanced activity of CTX/dCTX against pathogens producing meningitis compared to ceftriaxone and other contemporary therapeutic agents [1].
• Similarly, CTX plus dCTX have been described as being synergist in their activity against greater than 70% of Enterobacteriaceae or staphylococci and greater than 80% of anaerobic bacteria [1].
• Against Gram-positive bacteria, HR 221 showed 100% inhibition of growth of Streptococcus pneumoniae at 0.39 microgram/ml, and it was slightly less active against Staphylococcus aureus (MIC90:12.5 micrograms/ml) than other antibiotics such as cefotaxime (CTX) [2].

High impact information on cefotaxime

• Strains with substitutions within a conserved amino acid motif changing STMK to SAFK and a Leu-to-Val change just before the KSG motif were highly resistant to CTX (MIC, >==2 microgram/ml) [3].
• The dCTX compound was classified as a drug with a potency superior to a "second-generation" cephalosporin and possessed greater beta-lactamase stability against some enzymes compared to CTX [1].

References